These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 15823493)

  • 21. [Prevention, treatment and management of inflammation in atherosclerosis].
    Takemoto M; Yokote K
    Nihon Rinsho; 2011 Jan; 69(1):18-24. PubMed ID: 21226254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
    Ballantyne CM; Hoogeveen RC; Bang H; Coresh J; Folsom AR; Heiss G; Sharrett AR
    Circulation; 2004 Feb; 109(7):837-42. PubMed ID: 14757686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Critical appraisal of inflammatory markers in cardiovascular risk stratification.
    Krintus M; Kozinski M; Kubica J; Sypniewska G
    Crit Rev Clin Lab Sci; 2014 Oct; 51(5):263-79. PubMed ID: 24918900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention.
    Anderson JL
    Am J Cardiol; 2008 Jun; 101(12A):23F-33F. PubMed ID: 18549868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biomarkers, C-reactive proteins and statins in acute coronary syndromes.
    Ray KK
    Fundam Clin Pharmacol; 2007 Nov; 21 Suppl 2():31-3. PubMed ID: 18001319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress.
    Koenig W; Twardella D; Brenner H; Rothenbacher D
    Arterioscler Thromb Vasc Biol; 2006 Jul; 26(7):1586-93. PubMed ID: 16627803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease.
    Sudhir K
    J Clin Endocrinol Metab; 2005 May; 90(5):3100-5. PubMed ID: 15713711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inflammation, C-reactive protein, and atherothrombosis.
    Ridker PM; Silvertown JD
    J Periodontol; 2008 Aug; 79(8 Suppl):1544-51. PubMed ID: 18673009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inflammation and the development of atherosclerosis.
    Mizuno Y; Jacob RF; Mason RP
    J Atheroscler Thromb; 2011; 18(5):351-8. PubMed ID: 21427505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-Sensitivity C-Reactive Protein and Statin Initiation.
    Trpkovic A; Stanimirovic J; Rizzo M; Resanovic I; Soskic S; Jevremovic D; Isenovic ER
    Angiology; 2015 Jul; 66(6):503-7. PubMed ID: 25053677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature.
    Patrick L; Uzick M
    Altern Med Rev; 2001 Jun; 6(3):248-71. PubMed ID: 11410071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship of C-reactive protein, metabolic syndrome and diabetes mellitus: potential role of statins.
    Nash DT
    J Natl Med Assoc; 2005 Dec; 97(12):1600-7. PubMed ID: 16396052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Utility of Lp-PLA2 in lipid-lowering therapy.
    Racherla S; Arora R
    Am J Ther; 2012 Mar; 19(2):115-20. PubMed ID: 20634673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. View of statins as antimicrobials in cardiovascular risk modification.
    Kozarov E; Padro T; Badimon L
    Cardiovasc Res; 2014 Jun; 102(3):362-74. PubMed ID: 24623278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Altering the pathophysiology of atherosclerosis: the multidimensional role of statins.
    Clearfield MB
    J Am Osteopath Assoc; 2010 Apr; 110(4 Suppl 4):S2-6. PubMed ID: 20453192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients.
    Tsimikas S; Willerson JT; Ridker PM
    J Am Coll Cardiol; 2006 Apr; 47(8 Suppl):C19-31. PubMed ID: 16631506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Anti-Inflammatory Effects of Statins on Coronary Artery Disease: An Updated Review of the Literature.
    Diamantis E; Kyriakos G; Quiles-Sanchez LV; Farmaki P; Troupis T
    Curr Cardiol Rev; 2017; 13(3):209-216. PubMed ID: 28462692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inflammatory Biomarkers and Atherosclerosis.
    Soeki T; Sata M
    Int Heart J; 2016; 57(2):134-9. PubMed ID: 26973275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of statin therapy on lipoprotein associated phospholipase A2 levels.
    Albert MA; Glynn RJ; Wolfert RL; Ridker PM
    Atherosclerosis; 2005 Sep; 182(1):193-8. PubMed ID: 15982658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inflammatory biomarkers in coronary artery disease.
    Zakynthinos E; Pappa N
    J Cardiol; 2009 Jun; 53(3):317-33. PubMed ID: 19477372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.